Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
peginterferon alfa-2b + nucleos(t)ide analogues
- Development stage
- Preclinical
- Lead developer
- Shenzhen Third People's Hospital
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
Peginterferon alfa-2b + nucleos(t)ide analogues is a combination therapy being investigated by Shenzhen Third People's Hospital for the treatment of chronic hepatitis B (CHB). Peginterferon alfa-2b is a pegylated cytokine that binds to the interferon alpha/beta receptor (IFNAR), triggering a signaling cascade that induces an antiviral state and enhances the host immune response against the hepatitis B virus. Nucleos(t)ide analogues (NAs), such as entecavir or tenofovir, are small molecule inhibitors of the HBV DNA polymerase/reverse transcriptase, which directly suppress viral replication by acting as chain terminators. This combination regimen is specifically being studied in a prospective cohort to evaluate its ability to achieve HBsAg clearance (functional cure) in CHB patients, including those with metabolic dysfunction-associated steatotic liver disease (MASLD).
- Other names
- Peg-IFN α-2b + NAsPegylated interferon alpha-2b + nucleos(t)ide analogues
02
Targets
IFNAR2 (Interferon alpha/beta receptor subunit 2)HBV Pol (Hepatitis B virus polymerase)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on peginterferon alfa-2b + nucleos(t)ide analogues.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on peginterferon alfa-2b + nucleos(t)ide analogues.